Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28177904 | 0.82 | KDM4E (0.42) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL2585276 | 0.82 | KDM4E (0.45) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL17484629 | 0.82 | KDM4E (0.42) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL20518637 | 0.82 | KDM4E (0.45) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| Bromide SCHEMBL28354965 | 0.80 | KDM4E (0.44) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| Hydrochloric Acid SCHEMBL27966647 | 0.80 | KDM4E (0.44) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL27673215 | 0.80 | KDM4E (0.41) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL20518717 | 0.79 | KDM4E (0.41) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL20518716 | 0.79 | KDM4E (0.41) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 | |
| SCHEMBL10576923 | 0.77 | KMT2A (0.50) | KDM4ETBXA2RCYP19A1KMT2ACYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982095-B2 | Substituted organopolysiloxanes and use thereof | PHOSPHONICS LTD (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20090098082-A1 | substiuted organopolysiloxanes and use thereof | PHOSPHONICS LTD (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1786850-B1 | SUBSTITUTED ORGANOPOLYSILOXANES AND USE THEREOF | PHOSPHONICS LTD (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008099165-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1786850-A1 | SUBSTITUTED ORGANOPOLYSILOXANES AND USE THEREOF | Phosphonics LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006013060-A1 | SUBSTITUTED ORGANOPOLYSILOXANES AND USE THEREOF | PHOSPHONICS LTD (GB) | 2006-02-09 | — | — | WO | disclosed |
| CN-1037511-C | Therapeutic agents | BOOTS CO PLC (GB) | 1998-02-25 | — | — | CN | disclosed |
| EP-0061624-B1 | CATIONIC DYES AND THEIR USE | BASF Aktiengesellschaft (DE) | 1985-02-20 | — | — | EP | disclosed |
| EP-0061624-A1 | Cationic dyes and their use | BASF Aktiengesellschaft (DE) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098082-A1 | substiuted organopolysiloxanes and use thereof | OR10J3, SOST, ITGB3 | KDM4E 4077/4885TBXA2R 2644/4885CYP19A1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.